Key facts
- Trailhead Biosystems’s last known valuation is $38.6M (Nov 2023).
- It has raised $61.6M across 4 recorded rounds; the latest was Early Stage VC ($20.0M) in Jun 2024.
- Notable investors include Ohio Department of Development, MAK Capital, Advanced Regenerative Manufacturing Institute, Global Cardiovascular Innovation Center, Innovation Fund America — 6 tracked in total.
- Trailhead Biosystems has filed 7 Form Ds with the SEC since 2020, most recently May 2025 ($20.0M sold to 2 investors).
- Status: Privately Held (backing).
- ·Post-money valuations for all 4 rounds
- ·The complete investor list — 6 names
- ·Watchlist + deal alerts for Trailhead Biosystems
Funding rounds
4 roundsAbout Trailhead Biosystems
Developer of iPSC-derived research cell products and differentiation technologies designed to enable consistent and scalable human cell models. The company offers ready-to-use cell products, custom differentiation services, and a high-dimensional design-of-experiments platform integrating computational modeling, automation, and large-scale data generation, enabling researchers and drug developers to achieve reproducible, high-purity cell differentiation and accelerate disease modeling and preclinical research.
- Sector
- Healthcare
- HQ
- Beachwood, OH, United States
- Founded
- 2015
- Employees
- 49
- Website
- trailbio.com/
- Ownership
- Privately Held (backing)
Trailhead Biosystems doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Trailhead Biosystems shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Trailhead Biosystems in its N-PORT filings yet. We sweep new filings monthly.